Brief: Galera Reports Q1 2023 Financial Results And Recent Corporate Updates

Obsidian Therapeutics

11/05/2023 13:48

May 11 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND
RECENT
CORPORATE UPDATES
    * Q1 LOSS PER SHARE $0.50
    * GALERA THERAPEUTICS- AVASOPASEM NDA GRANTED FDA PRIORITY
REVIEW
FOR RADIOTHERAPY-INDUCED SEVERE ORAL MUCOSITIS; PDUFA TARGET
DATE OF AUGUST 9, 2023
    * AS OF MARCH 31, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS OF $47.8 MILLION
    * Q1 EARNINGS PER SHARE VIEW $-0.38 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1cL7XH 
Further company coverage:  GRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))